Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison

杜皮鲁玛 医学 美波利祖马布 生活质量(医疗保健) 内科学 临床试验 慢性阻塞性肺病 呼吸系统 免疫学 重症监护医学 随机对照试验 呼吸道疾病
作者
Surya P. Bhatt,Nick Freemantle,Mena Soliman,J. Heble,Yann Cabon,Ernesto Mayen Herrera,Joe Yang,Yingxin Xu
出处
期刊:Pulmonary therapy [Adis, Springer Healthcare]
卷期号:12 (1): 201-217 被引量:1
标识
DOI:10.1007/s41030-025-00322-1
摘要

Up to 40% of patients with chronic obstructive pulmonary disease (COPD) exhibit elevated blood eosinophils, reflective of type 2 inflammation. Dupilumab and mepolizumab versus standard of care have demonstrated moderate-to-severe exacerbation reductions of 30–34% and 15–18%, respectively, over 52 weeks. This study compared their relative efficacy using indirect treatment comparison (ITC). A Bucher ITC was performed on 52-week phase 3 trials of dupilumab (BOREAS/NOTUS) and mepolizumab (MATINEE/METREX/METREO). The primary ITC endpoint was annualized moderate-to-severe exacerbation rates in patients from BOREAS + NOTUS versus MATINEE + METREX (modified intention-to-treat high stratum cohort, representing an eosinophilic phenotype); sensitivity analyses were performed using different combinations of mepolizumab data including MATINEE + METREX + METREO (100-mg arm). Other 52-week endpoints included mean difference in pre-bronchodilator forced expiratory volume in 1 s (FEV1), proportion of St. George’s Respiratory Questionnaire (SGRQ) improvement ≥ 4 points, proportion of Evaluating Respiratory Symptoms in COPD (E-RS:COPD) improvement ≥ 2 points, and annualized severe exacerbation rate. Rate ratios (RRs)/odds ratios (ORs) with 95% confidence intervals (CIs) are reported. The primary ITC resulted in an RR of 0.82 (95% CI 0.66, 1.01), showing a numerical advantage for dupilumab versus mepolizumab in reducing moderate-to-severe exacerbation. Sensitivity analyses confirmed findings from the primary ITC (BOREAS + NOTUS vs. MATINEE + METREX + METREO: RR 0.83 [95% CI 0.68, 1.01]). Dupilumab demonstrated significantly greater FEV1 improvement (mean difference 83.4 mL [95% CI 36.1, 130.7]) and proportion of E-RS:COPD improvement ≥ 2 points (OR 1.71; [95% CI 1.18, 2.48]), with a numerical difference favoring dupilumab for the proportion of SGRQ improvement ≥ 4 points (OR 1.16; [95% CI 0.86, 1.56]) and for annualized severe exacerbation rate (RR 0.61 [95% CI 0.33, 1.13]) versus mepolizumab. This ITC suggests potential clinical benefits of dupilumab over mepolizumab in reducing exacerbations and improving lung function, respiratory symptoms, and quality of life in patients with COPD and type 2 inflammation. Direct head-to-head trials are necessary to confirm these results and better guide treatment choices. Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that causes breathing difficulties and frequent flare-ups, also known as exacerbations. In some people with COPD, a type of inflammation known as type 2 inflammation is present. This inflammation is often linked to higher levels of white blood cells called eosinophils. These patients may be more likely to experience exacerbations and worsening symptoms. Two injectable treatments, dupilumab and mepolizumab, have recently been studied in people with COPD who have this type of inflammation (so-called eosinophilic phenotype). Both drugs have shown benefits when added to triple inhaler therapy regimen, but they have not been directly compared in the same clinical trial. This study used a method called an indirect treatment comparison, which uses results from dupilumab and mepolizumab trials to estimate how well these two treatments compare. The results indicate a trend suggesting that dupilumab may offer greater benefit than mepolizumab in reducing the number of moderate or severe COPD exacerbations. People treated with dupilumab also experienced better lung function and were more likely to report fewer breathing symptoms, as well as improved quality of life. Although safety comparisons were not part of the indirect treatment comparison, safety results from dupilumab and mepolizumab trials appeared to be similar. These findings suggest that dupilumab may offer greater overall benefits for people with COPD and type 2 inflammation. However, direct head-to-head trials are necessary to confirm these results and better guide treatment choices.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被ZX801采纳,获得10
刚刚
刚刚
1秒前
3秒前
忧伤的南莲完成签到,获得积分10
3秒前
111发布了新的文献求助10
3秒前
3秒前
是唐朝越啊完成签到,获得积分10
4秒前
LGL发布了新的文献求助10
4秒前
YAYING发布了新的文献求助10
6秒前
鹿饮溪发布了新的文献求助10
6秒前
王乐乐发布了新的文献求助10
7秒前
zhangyi完成签到 ,获得积分10
7秒前
占曼荷完成签到,获得积分20
7秒前
只只完成签到,获得积分10
7秒前
Taikonaut发布了新的文献求助10
7秒前
jiehe完成签到,获得积分10
8秒前
小蘑菇的应助被lqiu采纳,获得10
8秒前
水蜜桃完成签到,获得积分10
8秒前
无花果的应助被飞鸿影下采纳,获得10
9秒前
AXQ完成签到,获得积分10
11秒前
CDabin完成签到,获得积分10
11秒前
Jasper的应助被欣喜若魔采纳,获得20
11秒前
科研通AI6.2的应助被llll采纳,获得10
11秒前
椰妃完成签到,获得积分10
12秒前
传统的冷霜完成签到,获得积分10
13秒前
小西门完成签到,获得积分10
14秒前
研友_Z6Qrbn发布了新的文献求助10
15秒前
Eric的应助被少双采纳,获得10
15秒前
15秒前
李爱国的应助被哈斯u和采纳,获得10
16秒前
鹿饮溪完成签到,获得积分20
18秒前
18秒前
18秒前
汤包发布了新的文献求助10
19秒前
欣喜若魔完成签到,获得积分10
20秒前
21秒前
Jigsaw发布了新的文献求助10
21秒前
21秒前
想吃小面包完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578698
关于积分的说明 21861559
捐赠科研通 7791583
什么是DOI,文献DOI怎么找? 3436814
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483582